- Home
- HTH vs HTFL Comparison
HTH vs HTFL Comparison
Compare HTH & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | HTH | HTFL |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | 843 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 2003 | N/A |
Fundamental Metrics
Financial Performance| Metric | HTH | HTFL |
|---|---|---|
| Price | $39.23 | $35.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $37.50 | ★ $38.20 |
| AVG Volume (30 Days) | 276.7K | ★ 1.2M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 51.72 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $152,188,000.00 | N/A |
| Revenue This Year | N/A | $27.66 |
| Revenue Next Year | $3.22 | $23.55 |
| P/E Ratio | $60.44 | ★ N/A |
| Revenue Growth | ★ 15.52 | N/A |
| 52 Week Low | $29.20 | $20.13 |
| 52 Week High | $40.41 | $41.22 |
Technical Indicators
Market Signals| Indicator | HTH | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 62.43 | 67.94 |
| Support Level | $36.20 | $28.03 |
| Resistance Level | $40.41 | $37.93 |
| Average True Range (ATR) | 0.80 | 1.86 |
| MACD | 0.14 | 0.49 |
| Stochastic Oscillator | 99.81 | 95.69 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.